Parminder Singh, MD

Parminder Singh, MD, discusses potential implications of the phase III IMvigor130 trial in advanced bladder cancer.

Parminder Singh, MD, discusses the improvement in overall response rates with immunotherapy, targeted therapy, and antibody-drug conjugates in advanced urothelial cancer.

Parminder Singh, MD, discusses combination treatments that are being evaluated in localized bladder cancer.

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses research being done with antibody-drug conjugates (ADCs) in advanced bladder cancer.

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses investigational immunotherapy combinations in urothelial cancer.

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses the prevalence of genomic testing in urothelial cancer.

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses the evolving role of chemotherapy in the treatment of bladder cancer.

Parminder Singh, MD, Hematologist/Oncologist, Mayo Clinic, discusses treatment selection for patients with bladder cancer. At this point, patient selection is based on the approval or labeling indications of the drug, where the patient lies in the spectrum of disease, and whether or not they have any alternative options.